Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.

Basic & clinical pharmacology & toxicology - 1 Jun 2016

Mukai Yuji, Senda Asuna, Toda Takaki, Eliasson Erik, Rane Anders, Inotsume Nobuo

Abstract excerpt

The aim of the present study was to further investigate a previously identified metabolic interaction between losartan and paclitaxel, which is one of the marker substrates of CYP2C8, by using human liver microsomes (HLMs) from donors with different CYP2C8 and CYP2C9 genotypes. Although CYP2C8 and CYP2C9 exhibit genetic linkage, previous studies have yet to determine whether losartan or its active metabolite,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Cytochrome P-450 CYP2C8

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Inhibitory Concentration 50

Share to Losartan

Share to Microsomes, Liver

Share to Paclitaxel

Share to Taxoids

Source

Identifiers

PMID: 26551762
DOI: 10.1111/bcpt.12520

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.PMID 26551762Read ↗

Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes.Semantic proximity Read ↗

Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4.Semantic proximity Read ↗

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.Semantic proximity Read ↗

Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation.Semantic proximity Read ↗

Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.Semantic proximity Read ↗

Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro.Semantic proximity Read ↗

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.Semantic proximity Read ↗

Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel.Semantic proximity Read ↗

Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.Semantic proximity Read ↗

Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.Semantic proximity Read ↗

Site-directed mutation studies of human liver cytochrome P -450 isoenzymes in the CYP2C subfamilySemantic proximity Read ↗

Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5'-hydroxylation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.